Credit Suisse reiterated coverage on Galecto with a new price target
$GLTO
Biotechnology: Pharmaceutical Preparations
Health Care
Credit Suisse reiterated coverage of Galecto with a rating of Outperform and set a new price target of $7.00 from $12.00 previously